Yingke PE

Yingke Capital is a leading Chinese private equity firm specializing in the biopharmaceutical and healthcare sectors. Founded in 2010, the firm has established a comprehensive investment ecosystem covering the entire industry chain, including innovative drugs, medical devices, and healthcare services. It is known for its industrial investment strategy, often taking significant stakes in high-growth biotech companies and supporting them through IPOs. Yingke Capital has invested in numerous prominent Chinese biotech firms such as Cansino Biologics, RemeGen, and Zai Lab. The firm manages substantial assets and is recognized as one of the most active healthcare investors in China. Headquartered in Shanghai, it maintains a strong presence across major Chinese financial hubs to identify and nurture emerging leaders in the life sciences space.